Article Sidebar
Views PDF: 124
RESULTS OF CETUXIMAB PLUS PLATINUM-BASED CHEMOTHERAPY AS THE FIRST LINE THERAPY OF RECURRENT OR METASTATIC SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK
Main Article Content
Abstract
A cross-sectional descriptive prospective and retrospective study evaluated the efficacy of first-line cetuximab plus platinum-based chemotherapy for 27 patients with recurrent or metastatic squamous-cell carcinoma of the head and neck at K Hospital from January 2019 to March 2023. Response rate, progression-free survival (PFS), overall survival (OS), and adverse effects were evaluated. The results showed the response rate was 44.5%; disease control rate was 77.8%. The median FPS was 6.2 months, and the median OS was 12 months. The most common adverse events included rash acneiform, anemia, neutropenia, diarrhea and nausea, vomiting, about 40 -50% at all grade, however, most toxicities were grade 1-2, with fewer cases of grade 3-4 toxicity. In conclusion, cetuximab combined with platinum-based chemotherapy as first-line treatment for recurrent or metastatic squamous-cell carcinoma of the head and neck yielded favorable results with acceptable toxicity, in line with global studies.
Article Details
References
2. Jacobs C, Lyman G, Velez-García E, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992; 10:257.
3. Clavel M, Vermorken JB, Cognetti F, et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 1994; 5:521.
4. Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2005; 23:3562.
5. Schöffski P, Catimel G, Planting AS, et al. Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group. Ann Oncol 1999; 10:119.
6. Glisson BS, Murphy BA, Frenette G, et al. Phase II Trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck. J Clin Oncol 2002; 20:1593.
7. Specht L, Larsen SK, Hansen HS. Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous-cell carcinoma of the head and neck. Ann Oncol 2000; 11:845.
8. Baur M, Kienzer HR, Schweiger J, et al. Docetaxel/cisplatin as first-line chemotherapy in patients with head and neck carcinoma: a phase II trial. Cancer 2002; 94:2953.
9. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359: 1116.
10. Guigay, J., Aupérin, A., Fayette, J., et al. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial. The Lancet Oncology, 2021. 22(4), 463–475.